Clinical Trial

A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema

Study acronym: OPTIMAL-3
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study is to assess the use of Artificial intellignce (AI) to predict eye treatment changes in adult participants with diabetic macular edema (DME).
Trial Details
NCT Number NCT07604545
Lead Sponsor AbbVie
Conditions Diabetic Macular Edema
Enrollment 554 participants
Start Date 2026-05-30
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-22